The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.
 
Lian Liu
No Relationships to Disclose
 
Song Li
No Relationships to Disclose
 
Zimin Liu
No Relationships to Disclose
 
Yanguo Liu
No Relationships to Disclose
 
Kainan Li
No Relationships to Disclose
 
Lei Cong
No Relationships to Disclose
 
Fangli Cao
No Relationships to Disclose
 
Aina Liu
No Relationships to Disclose
 
Haiyan Liu
No Relationships to Disclose
 
Ling Li
No Relationships to Disclose
 
Linli Qu
No Relationships to Disclose
 
Yi Zhai
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Jisheng Li
No Relationships to Disclose
 
Duanbo Shi
No Relationships to Disclose
 
Jiahui Chu
No Relationships to Disclose
 
Di Zhang
No Relationships to Disclose
 
Zhaodi Nan
No Relationships to Disclose
 
Qian Xu
No Relationships to Disclose
 
Shulun Nie
No Relationships to Disclose